Stock listing
OTC:CARM Carisma Therapeutics, Inc. Stock
Follow Carisma Therapeutics, Inc. into a list and get an email when it puts out news.

- Ticker
- OTC:CARM
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Carisma Therapeutics, Inc. on 6ix
- Decks
- 1 deck · latest 2024
Valuation
balance Sep 30, 2025
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -1.02
Forecasts
1 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 USD · Analysts' mean
- EPS, year to Dec 2025
- -0.69 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Steven Kelly | President, Chief Executive Officer and Director |
| Richard Morris | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Marella Thorell | Director |
| Steven Kelly | President, Chief Executive Officer and Director |
Events
| Quarter | Results |
|---|---|
| Q3 2025 | Nov 12, 2025 |
| Q2 2025 | Aug 7, 2025 · After close |
| Q1 2025 | May 13, 2025 · After close |
| Q4 2024 | Mar 31, 2025 · Before open |
| Q3 2024 | Nov 7, 2024 · Before open |
| Q2 2024 | Aug 8, 2024 · Before open |
| Q1 2024 | Apr 1, 2024 · Before open |
| Q4 2023 | Mar 6, 2024 · After close |
| Q3 2023 | Nov 9, 2023 · Before open |
| Q2 2023 | Aug 10, 2023 · Before open |
All 20 quarters
| Quarter | Results |
|---|---|
| Q1 2023 | May 11, 2023 · Before open |
| Q4 2022 | Feb 28, 2023 · Before open |
| Q3 2022 | Nov 7, 2022 · Before open |
| Q2 2022 | Aug 8, 2022 · Before open |
| Q1 2022 | May 9, 2022 · Before open |
| Q4 2021 | Feb 28, 2022 · Before open |
| Q3 2021 | Nov 8, 2021 · Before open |
| Q2 2021 | Aug 9, 2021 · Before open |
| Q1 2021 | May 10, 2021 · Before open |
| Q4 2020 | Mar 15, 2021 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2024) | Investor deck | 69 slides | 2024 |
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.6M | 14.9M | 9.83M | 26.5M | 11.2M | 425.0K | 30.0M | 990.0K | ||
| Cost of revenue | 59.7M | 74.1M | 6.09M | 85.0K | 219.0K | 208.0K | ||||
| Gross profit | -40.0M | -59.2M | 9.83M | 26.5M | 11.2M | -219.0K | -208.0K | 425.0K | 30.0M | 990.0K |
| Research and development | 59.7M | 74.1M | 56.6M | 25.2M | 23.3M | 24.4M | 13.9M | 12.2M | 12.2M | 26.0M |
| Selling, general and administrative | 20.1M | 29.5M | 9.38M | 6.41M | 5.09M | 12.2M | 11.6M | 8.07M | 14.7M | 9.85M |
| Operating income | -62.2M | -88.7M | -56.2M | -28.2M | -28.4M | -36.9M | -25.7M | -20.0M | 6.17M | -35.2M |
| Depreciation and amortization | 3.35M | 2.84M | 6.09M | 682.0K | 448.0K | 219.0K | 208.0K | 285.0K | 178.0K | 366.0K |
| EBITDA | -58.8M | -85.9M | -50.1M | -27.5M | -27.9M | -36.7M | -25.5M | -19.7M | 6.34M | -34.8M |
| Interest expense | 1.94M | 3.15M | 8.26M | 1.47M | 247.0K | 1.40M | ||||
| Income before tax | -60.5M | -86.9M | -61.2M | -8.61M | -28.3M | -107.5M | -33.7M | -29.0M | 1.90M | -33.5M |
| Income tax | -60.5M | 8.10M | -3.88M | -8.27M | -29.0K | 46.9K | 5.00K | 1.40M | ||
| Net income | -60.5M | -86.9M | -61.2M | -336.0K | -28.3M | -107.5M | -33.7M | -29.0M | 1.89M | -33.5M |
| Earnings per share, basic | -1.46 | -2.59 | -1.52 | -0.04 | -4.80 | -23.65 | -10.91 | -22.24 | 1.74 | -35.23 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.9M | 77.6M | 24.2M | 162.6M | 55.4M | 48.1M | 50.4M | 14.7M | 25.3M | 36.1M |
| Short-term investments | 925.0K | 0 | 27.8M | |||||||
| Receivables | 2.86M | 825.0K | 24.5M | |||||||
| Inventory | -825.0K | -24.5M | ||||||||
| Current assets | 23.8M | 80.5M | 54.6M | 205.6M | 62.9M | 54.4M | 51.8M | 15.0M | 25.9M | 36.3M |
| Property, plant and equipment | 13.4M | 5.66M | 5.19M | |||||||
| Goodwill | 13.1M | 13.1M | 13.1M | 13.1M | 13.1M | 16.9M | ||||
| Total assets | 30.5M | 89.6M | 72.2M | 312.6M | 188.5M | 114.4M | 111.6M | 75.1M | 104.1M | 36.8M |
| Accounts payable | 2.08M | 3.93M | 1.73M | 2.85M | 3.10M | 1.90M | 1.37M | 907.0K | 1.67M | 1.25M |
| Current liabilities | 16.1M | 15.9M | 19.7M | 11.6M | 18.0M | 8.52M | 6.11M | 4.72M | 3.98M | 7.58M |
| Long-term debt | 33.7M | |||||||||
| Total debt | 2.48M | 3.12M | 40.2M | 2.63M | 3.44M | 13.9M | ||||
| Total liabilities | 58.4M | 63.0M | 214.8M | 140.9M | 197.7M | 141.1M | 67.4M | 57.1M | 65.4M | 17.9M |
| Shareholders' equity | -27.9M | 26.5M | -157.1M | 171.7M | -9.23M | -26.7M | 44.2M | 18.0M | 38.7M | 18.9M |
| Shares outstanding | 41.5M | 33.5M | 40.3M | 9.12M | 5.91M | 4.55M | 3.09M | 1.30M | 1.09M | 949.6K |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -59.9M | -81.2M | -7.57M | -37.3M | -27.0M | -37.5M | -22.8M | -17.8M | 2.62M | -34.5M |
| Capital spending | -123.0K | -1.13M | -4.66M | -1.87M | -440.0K | -136.0K | -2.00K | 0 | 0 | -287.0K |
| Free cash flow | -60.0M | -82.3M | -12.2M | -39.2M | -27.5M | -37.7M | -22.8M | -17.8M | 2.62M | -34.8M |
| Cash from investing | -123.0K | 72.4M | -32.6M | -1.87M | -440.0K | -136.0K | -2.00K | 98.0K | 461.0K | -287.0K |
| Cash from financing | 344.0K | 62.2M | 35.8M | 16.0M | 72.3M | 35.4M | 58.6M | 7.00M | -13.8M | 16.8M |
| Dividends paid | -147.0K | |||||||||
| Change in cash | -59.7M | 53.4M | -138.4M | -23.2M | 44.8M | -2.30M | 35.7M | -10.7M | -10.7M | -18.0M |
Cap table
Built by 6ix from Carisma Therapeutics, Inc.’s releases
- Common shares
- 41,845,078
- Fully diluted
- 41,845,078
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 41,845,078 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 41,845,078 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Briggs Morrison Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025); Werewolf Therapeutics, Inc. (Director · Since at least Apr 29, 2021); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 11, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past) | Director · Mar 7, 2023 – Jun 26, 2024 · Past |
| John Hohneker Other companies: ArriVent BioPharma, Inc. (Director · Since at least May 16, 2024); Curis, Inc. (Director · Since at least Dec 2, 2021); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past) | Director · Apr 1, 2024 – Jun 26, 2024 · Past |
| Marella Thorell Other companies: Seres Therapeutics, Inc. (EVP, Chief Financial Officer · Since at least Mar 25, 2024); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Evelo Biosciences, Inc. (Chief Financial Officer · Jul 13, 2022 – Nov 7, 2023 · Past); Centessa Pharmaceuticals PLC (Chief Accounting Officer · May 27, 2021 – Mar 21, 2022 · Past); GRI Bio, Inc. (Director · Feb 9, 2021 – Dec 13, 2022 · Past) | Director · Since at least Jun 30, 2024 |
| David Scadden Other companies: Editas Medicine, Inc. (Director · Since at least Feb 5, 2019); Agios Pharmaceuticals, Inc. (Independent Director · Since at least May 27, 2017); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past) | Director · Jun 30, 2024 – Jul 1, 2024 · Past |
| Michael Torok Other companies: Amarin Corporation plc (Non-Executive Director · Since at least Apr 3, 2025) | Director · Mar 7, 2023 – Jun 26, 2024 · Past |
| Sohanya Cheng Other companies: Karyopharm Therapeutics Inc. (EVP & Chief Commercial Officer · Since at least Jun 7, 2021) | Director · Oct 31, 2024 – Oct 31, 2024 · Past |
| Steven Kelly Other companies: Artelo Biosciences, Inc. (Director · Since at least Jun 21, 2019) | President and CEO, Director · Mar 7, 2023 – Jan 28, 2025 · Past |
| Bjorn Odlander | Director · Mar 7, 2023 – Mar 7, 2023 · Past |
| Natalie McAndrew | Vice President of Finance · Jan 1, 2025 – Jan 1, 2025 · Past |
Log in to ask 6ix AI your own questions about Carisma Therapeutics, Inc.